The story of the scleroderma drug candidate FT011 is one of “tenacity and persistence,” said Darren Kelly, CEO and managing director of Certa Therapeutics, which is developing the drug. The drug was discovered around 2006 by Kelly’s laboratory at the University of Melbourne and Spencer Williams of the Bio21 Institute. “It was really [Williams] being the…
FT011 yielded significant clinical improvements in more than 60% of scleroderma patients
Certa Therapeutics, a Melbourne-based biotech company, announced the results of its Phase 2 clinical trial for FT011, a novel oral therapy for chronic fibrosis. The trial showed clinically meaningful improvements in more than 60% of scleroderma patients after 12 weeks of treatment. In the Phase 2 study, 60% of patients treated with a 400 mg…